Dr. May earned a PhD from Max Planck Institute for Biochemistry in Martinsried, Germany and an MBA from INSEAD, Fontainebleau, France.
Klaus May is a Senior Advisor focused on Asian life sciences organizations and markets, and is based in Tokyo, Japan. Dr. May has over 20 years of international experience in healthcare consulting, investment banking, product partnering and start-ups. He has worked intensively across Asia for the past 10 years. Dr . May is also experienced in cross-border M&A transactions, private equity projects, growth strategy, and corporate turn-arounds.
Prior to joining JSB-Partners, Dr. May founded a specialty pharma business focusing on South and Southeast Asia, in which he still is a board member. Before that, Dr. May served as Global Head of Healthcare and Chemicals Advisory with ABN Amro, working out of its Amsterdam and Tokyo offices. In that capacity, he focused on cross-border transactions between Asian and European companies, among other initiatives. Before joining ABN Amro, Dr. May was a senior member of The Boston Consulting Group’s Healthcare practice in its Paris and Dusseldorf offices.
Dr. May is a member of the board of directors of Sea Lion Pharma, Singapore. He previously served on the board of Ubbink bv, Netherlands.